Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago
25 mg
Strip (10): ৳300.00 Box (2 × 10 = 20): ৳600.00
৳30.00 per tablet

Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.

All price changes →
From ৳30.00 per tablet
Available as: 25 mg · 2 x 10

More from Mirasol XR

Other strengths and forms by Beximco Pharmaceuticals Ltd.

Indications & Uses

Megron ER tablet is used to relieve symptoms of overactive bladder (OAB) in adults, including urgency, frequent urination and urgency incontinence.

Pharmacology

Mirabegron is the first medicine in its class, known as a beta-3 adrenoceptor agonist. It works through two complementary pathways: acting directly on the smooth muscle of the bladder wall, and acting through the sensory nerves that supply the bladder. By activating beta-3 adrenoceptors, it raises levels of cyclic adenosine monophosphate (cyclic AMP), which relaxes the detrusor (bladder wall) muscle during the filling/storage phase of the bladder's fill-void cycle. The net effect is an increase in the bladder's capacity to hold urine.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

For adults, including elderly patients, the recommended starting dose is one Mirabegron 25 mg tablet taken once daily, with or without food. Depending on how well the individual patient responds and tolerates the medicine, the dose may be increased to one Mirabegron 50 mg tablet once daily.

In patients with renal or hepatic impairment, those with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child Pugh Class B) should not receive more than 25 mg of Mirabegron once daily. Mirabegron has not been studied in patients with end stage renal disease (GFR below 15 mL/min/1.73 m2, or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C), so its use is not recommended in these patient groups.

No dose adjustment is required based on gender. In the paediatric population, the safety and efficacy of Mirabegron in children under 18 years of age have not yet been established.

The Mirabegron tablet should be taken once daily with liquid, swallowed whole, and should not be chewed, divided, or crushed.

Side Effects

Tachycardia (fast heart rate) and urinary tract infections were the side effects most often reported with Megron ER 50 mg across three 12-week phase 3 trials, which were double-blind and placebo-controlled. Tachycardia occurred in 1.2% of patients on Megron ER 50 mg and caused 0.1% to stop treatment. Urinary tract infections occurred in 2.9% of patients on Megron ER 50 mg, but did not cause anyone to discontinue treatment. Among serious reactions, atrial fibrillation was reported in 0.2% of patients.

Cautions & Contraindications

Warnings & Precautions

Renal impairment: Megron ER has not been studied in patients with end stage renal disease, defined as a GFR below 15 mL/min/1.73 m2 or those requiring haemodialysis, and it is therefore not recommended for this group. Information is also limited for patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2); a pharmacokinetic study supports reducing the dose to 25 mg in these patients. Megron ER is not recommended for patients with severe renal impairment who are also taking strong CYP3A inhibitors. Hepatic impairment: Megron ER has not been studied in patients with severe hepatic impairment (Child Pugh Class C), so it is not recommended for this group. It is also not recommended for patients with moderate hepatic impairment (Child Pugh Class B) who are taking strong CYP3A inhibitors at the same time. Hypertension: Megron ER can raise blood pressure. Blood pressure should be checked before starting treatment and monitored periodically during treatment, particularly in patients who already have hypertension. Data are limited for patients with stage 2 hypertension, meaning a systolic reading of 160 mm Hg or higher or a diastolic reading of 100 mm Hg or higher. Patients with QT prolongation: Megron ER should be used with caution in patients who have congenital or acquired QT prolongation. Patients with bladder outlet obstruction (BOO) and patients on antimuscarinic medicines for OAB: A controlled clinical safety study in patients with bladder outlet obstruction (BOO) did not show an increase in urinary retention among those treated with Megron ER. Even so, Megron ER should be given with caution to patients who have clinically significant bladder outlet obstruction (BOO), and the same caution applies when it is given to patients who are taking antimuscarinic medicines for overactive bladder (OAB).

Contraindications

Mirabegron should not be used by anyone who is hypersensitive to the active substance or to any of its excipients. It is also contraindicated in patients with severe, uncontrolled hypertension, defined as a systolic blood pressure of 180 mmHg or higher and/or a diastolic blood pressure of 110 mmHg or higher.

Pregnancy & Breastfeeding

There is only limited data on the use of mirabegron in pregnant women. Studies in animals have shown reproductive toxicity, so mirabegron is not recommended during pregnancy or for women who are planning to become pregnant.

In rodents, mirabegron is excreted in milk, so it is expected to pass into human breast milk too. No studies have looked at how mirabegron affects milk production in humans, whether it appears in breast milk, or what effect it has on a breastfed child. For that reason, mirabegron should not be given during breastfeeding.

In animals, mirabegron had no treatment-related effect on fertility. Its effect on fertility in humans has not been established.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Overdose

Mirabegron has been given to healthy volunteers in single doses of up to 400 mg. At that dose, the volunteers reported palpitations and a pulse rate above 100 beats per minute (bpm). When healthy volunteers took multiple doses of up to 300 mg daily for 10 days, their pulse rate and systolic blood pressure went up. If someone takes an overdose of Mirabegron, treatment should be symptomatic and supportive. Pulse rate, blood pressure and ECG monitoring is recommended.

⚠️ In an emergency call 999 or go to the nearest hospital emergency department.

Storage

Keep Mirabegron in a cool, dry place, away from light.

Drug Interactions

Open checker →

Common questions about Mirasol XR 25 mg

What is Mirasol XR 25 mg Tablet (Extended Release)?

Mirasol XR 25 mg Tablet (Extended Release) is a medicine that contains Mirabegron. It is made by Beximco Pharmaceuticals Ltd. It belongs to the BPH/ Urinary retention/ Urinary incontinence group of medicines.

What is Mirasol XR used for?

Megron ER tablet is used to relieve symptoms of overactive bladder (OAB) in adults, including urgency, frequent urination and urgency incontinence.

What are the side effects of Mirasol XR?

Tachycardia (fast heart rate) and urinary tract infections were the side effects most often reported with Megron ER 50 mg across three 12-week phase 3 trials, which were double-blind and placebo-controlled. Tachycardia occurred in 1.2% of patients on Megron ER 50 mg and caused 0.1% to stop treatment.

Can I take Mirasol XR during pregnancy or while breastfeeding?

There is only limited data on the use of mirabegron in pregnant women. Studies in animals have shown reproductive toxicity, so mirabegron is not recommended during pregnancy or for women who are planning to become pregnant. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

What happens if I take too much Mirasol XR?

Mirabegron has been given to healthy volunteers in single doses of up to 400 mg. At that dose, the volunteers reported palpitations and a pulse rate above 100 beats per minute (bpm). In an emergency call 999 or go to the nearest hospital emergency department.

How should I store Mirasol XR?

Keep Mirabegron in a cool, dry place, away from light.

Can I take other medicines with Mirasol XR?

Some medicines can interact with Mirabegron, for example: Rifampicin, Clarithromycin, Digoxin, Itraconazole, Ritonavir, Ketoconazole. Tell your doctor or pharmacist about every medicine you take.

Is there a cheaper medicine with the same ingredient?

Mirasol XR is already among the lowest-priced brands of Mirabegron at this strength.

Do I need a prescription for Mirasol XR?

Mirasol XR is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 20 Aug 2026